Michael A Crilly1, Marjorie C Johnston, Corri Black. 1. Institute of Applied Health Sciences, Aberdeen University Medical School, Polwarth Building at Foresterhill, Aberdeen, AB25 2ZD, Scotland, UK, mike.crilly@abdn.ac.uk.
Abstract
PURPOSE: Rheumatoid arthritis (RA) is associated with extra-articular features (ExRA) and other co-morbidities. The aim of this study is to quantify their relative contribution to quality of life (QOL) in patients with RA. METHODS: A consecutive series of 114 ambulatory RA patients aged between 40 and 65 years were assessed by a research nurse on a single occasion. Assessment included a patient questionnaire (including EQ-5D), medication review and fasting venous blood sample. Medical records were reviewed by a rheumatologist for co-existing conditions. Multiple linear regression was used to adjust mean differences in EQ-5D in the presence/absence of co-existing conditions for age, sex, university education, arthritis duration, rheumatoid factor, erythrocyte sedimentation rate, current disease-modifying drug therapy, previous hand joint erosions and joint surgery. RESULTS: Mean age was 54 years (82% female) and median arthritis duration 10 years. Unadjusted EQ-5D was -0.09 (95% CI -0.18 to -0.01) lower in patients with any co-existing condition. EQ-5D scores were inversely correlated with the overall number of co-existing conditions (Spearman's ρ -0.31, p = 0.001), number of co-morbidities (ρ -0.22, p = 0.02) and number of ExRA features (ρ -0.22, p = 0.02). There was a linear trend of lower EQ-5D with increasing number of co-existing conditions (p = 0.003). EQ-5D was -0.18 (95% CI -0.33 to -0.02) lower in the presence of more than two co-existing conditions compared to none. Co-morbidity and ExRA features were associated with comparable adjusted reductions (-0.05 vs. -0.06) in EQ-5D scores. CONCLUSION: A wide range of co-existing conditions are associated with poorer QOL in patients with RA.
PURPOSE: Rheumatoid arthritis (RA) is associated with extra-articular features (ExRA) and other co-morbidities. The aim of this study is to quantify their relative contribution to quality of life (QOL) in patients with RA. METHODS: A consecutive series of 114 ambulatory RA patients aged between 40 and 65 years were assessed by a research nurse on a single occasion. Assessment included a patient questionnaire (including EQ-5D), medication review and fasting venous blood sample. Medical records were reviewed by a rheumatologist for co-existing conditions. Multiple linear regression was used to adjust mean differences in EQ-5D in the presence/absence of co-existing conditions for age, sex, university education, arthritis duration, rheumatoid factor, erythrocyte sedimentation rate, current disease-modifying drug therapy, previous hand joint erosions and joint surgery. RESULTS: Mean age was 54 years (82% female) and median arthritis duration 10 years. Unadjusted EQ-5D was -0.09 (95% CI -0.18 to -0.01) lower in patients with any co-existing condition. EQ-5D scores were inversely correlated with the overall number of co-existing conditions (Spearman's ρ -0.31, p = 0.001), number of co-morbidities (ρ -0.22, p = 0.02) and number of ExRA features (ρ -0.22, p = 0.02). There was a linear trend of lower EQ-5D with increasing number of co-existing conditions (p = 0.003). EQ-5D was -0.18 (95% CI -0.33 to -0.02) lower in the presence of more than two co-existing conditions compared to none. Co-morbidity and ExRA features were associated with comparable adjusted reductions (-0.05 vs. -0.06) in EQ-5D scores. CONCLUSION: A wide range of co-existing conditions are associated with poorer QOL in patients with RA.
Authors: Tae-Jin Lee; Bo Hyun Park; Hye Kyung Son; Ran Song; Ki Chul Shin; Eun Bong Lee; Yeong-Wook Song Journal: Value Health Date: 2012 Jan-Feb Impact factor: 5.725
Authors: Ines Rupp; Hendriek C Boshuizen; Catharina E Jacobi; Huibert J Dinant; Geertrudis van den Bos Journal: J Rheumatol Date: 2004-01 Impact factor: 4.666
Authors: Lorie L Geryk; Delesha M Carpenter; Susan J Blalock; Robert F DeVellis; Joanne M Jordan Journal: Clin Exp Rheumatol Date: 2015-03-24 Impact factor: 4.862
Authors: Leslie R Harrold; Ying Shan; Sabrina Rebello; Neil Kramer; Sean E Connolly; Evo Alemao; Sheila Kelly; Joel M Kremer; Elliot D Rosenstein Journal: Clin Rheumatol Date: 2020-03-04 Impact factor: 2.980